Isolation of Candidate Influenza Vaccine Viruses in Cell Culture
This Guideline lays down the quality recommendations for cells used to isolate candidate influenza vaccine viruses, the conditions under which the viruses are isolated and the subsequent passage of the viruses until the manufacturer's Master Seed is prepared under GMP conditions. This guideline replaces its draft version published under document reference EMA/CHMP/BWP/68803/2010. It should be read in conjunction with other relevant guideline documents like the introduction and general principles (4) and Part 1 of the Annex I to Directive 2001/83 or referneces like Ph. Eur. General chapter 5.2.3.
Get more information in the "Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture".
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs